A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome.
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2015
At a glance
- Drugs Mavoglurant (Primary)
- Indications Behavioural symptoms; Fragile X syndrome
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 08 Jul 2014 Status changed from active, no longer recruiting to completed as reported by clinicalTrials.gov record.
- 11 Jul 2013 Planned End Date changed from 1 Dec 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.